RedHill Biopharma Shares Outstanding History (RDHL)

RedHill Biopharma reported 50.92B shares outstanding at the end of fiscal 2025.

View full RedHill Biopharma company overview

RedHill Biopharma annual shares outstanding history

RedHill Biopharma annual shares outstanding

Fiscal yearPeriod endedShares outstandingChangeGrowth
20252025-12-3150.92B38.02B+294.76%
20242024-12-3112.90B153.0M+1.20%
20232023-12-3112.75B11.57B+980.50%
20222022-12-311.18B652.9M+123.92%
20212021-12-31526.8M142.9M+37.21%
20202020-12-31384.0M31.3M+8.87%
20192019-12-31352.7M69.0M+24.33%
20182018-12-31283.7M71.0M+33.36%
20172017-12-31212.7M

RedHill Biopharma shares outstanding trends

Over the last five fiscal years, RedHill Biopharma's shares outstanding moved from 384.0M to 50.92B, a change of 50.54B. The latest reported quarter, Q4 2025, shows 50.92B.

About the metric

What shares outstanding means

Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.

Calculation and source

SEC-reported period-end shares

TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review RedHill Biopharma source filings ↗

Community posts

It’s quiet here.

No posts about RDHL yet. Start the conversation.

Write the first post